Colorectal Cancer
Stay up to date on practice-changing data in community practice.
FDA Approves Retifanlimab, First Frontline Treatment for Advanced SCAC
With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of advanced anal cancer.
Read More
Behind the FDA Approval of Fruquintinib for Previously Treated mCRC
In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.
Listen
First-in-Human Data Highlight Potential of Intracellular Checkpoint Inhibition in Metastatic Colorectal Cancer
Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers
In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer
Managing Colorectal Cancer Requires Using All Available Options
In an interview with Peers & Perspectives in Oncology, John L. Marshall, MD, discussed treatment approaches and sequencing for refractory colorectal cancer.
FDA Approves Nivolumab/Ipilimumab Combo in MSI-H/dMMR mCRC
Based on data from the phase 3 CheckMate-8HW trial, the combination of nivolumab and ipilimumab has been approved by the FDA in metastatic colorectal cancer.
